From Scalpel to Light · Episode 6 of 10 · 12 min
The Virus as Courier
A virus is a package of genetic instructions, and medicine learned to empty it and fill it with a healthy gene. The episode follows gene delivery from the first gene therapy in 1990 through the death of Jesse Gelsinger in 1999, the leukemias in the French trial, and the comeback of the adeno-associated virus. It closes on costs, 2025 trial deaths, and a limit: a delivered gene has no off switch.
Who's who
- Jesse GelsingerEighteen-year-old volunteer who died in a 1999 gene therapy trial
- James Wilson+2 more episodesDirector of the University of Pennsylvania gene therapy institute
- Paul BergBiochemist who organized the 1975 Asilomar meeting
- Félix d'HérelleMicrobiologist who named the bacteriophage in 1917
- Alain FischerParis investigator whose immunodeficiency therapy cured most patients
- Marina Cavazzana-CalvoParis investigator in the French gene therapy trial
- Viviana Gradinaru+2 more episodesResearcher behind engineered vectors that cross into the brain in mice
- Benjamin DevermanResearcher behind recombinase-based vector selection
Where it happens
- Asilomar, CaliforniaSite of the 1975 recombinant DNA meeting
- National Institutes of Health, Bethesda, Maryland+1 more episodeSite of the first approved gene therapy protocol
- University of Pennsylvania, Philadelphia+1 more episodeWhere Gelsinger was treated in 1999
- Tbilisi, GeorgiaHome of the Eliava phage institute
Timeline
- February 1975More than 140 scientists meet at Asilomar and agree on containment rules
- September 14, 1990First authorized gene therapy given at the National Institutes of Health
- September 17, 1999Jesse Gelsinger dies four days after receiving an adenoviral vector
- 2002 to 2003Leukemia appears in children from the Paris trial
- December 2017Luxturna approved in the United States
- December 2023Casgevy, the first CRISPR medicine, approved
Still debated
Why Gelsinger reacted so much more severely than earlier participants is not fully settled, and how much conflicts of interest mattered remains a matter of interpretation. Who counts as the first gene therapy, the cause of a 2025 brain-swelling death, and phage therapy's efficacy are also unresolved.
